(PharmaNewsWire.Com, August 12, 2017 ) Report, "Metastatic Melanoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Metastatic Melanoma Report is to understand the market and pipeline status of the drugs around the Metastatic Melanoma to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Metastatic Melanoma. While the leading brands, companies and chemicals are considered thoroughly, report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.
1. Indication Overview 2. Market Drugs Landscape 2.1 Marketed Drugs 2.2 Marketed Details of Drugs by Application Type 2.3 Marketed Details of Drugs (NDA) by Marketing Status 2.4 Marketed Details of Drugs by Patent Expiration Timeline 3. Global API Manufacturers Assessment 3.1 API Manufacturers by United States Drug Master File (US DMF) Status 3.2 API Manufacturers by US DMF Status (Drug Specific) 3.3 API Manufacturers in Europe by Country 3.4 API Manufacturers in India by State 3.5 API Manufacturers in China by Province 3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape 4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs 4.2 API Manufacturers by US DMF Status (Drug Specific) 5. Drugs Market Data and Forecasted Sales Figure-2018 6. Marketed Drugs for Metastatic Melanoma 6.1 Drug Name 6.1.1 Drug Description 6.1.2 Global Active Pharmaceutical Manufacturers for Drug 6.1.3 Approval Status of Drug 6.1.4 Patent and Exclusivity Details for Drug 6.1.5 Company Profile and Financials 7. Phase III Drugs for Metastatic Melanoma 7.1 Drug Name 7.1.1 Drug Description 7.1.2 United States Drug Master File (DMF) 8. Discontinued Drugs for Metastatic Melanoma
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: